Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2014-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-014-2446-4PMID 24748417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis

  2012cited by this paper
• Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

  2012cited by this paper
• Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

  2011cited by this paper
• The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo

  2010cited by this paper
• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

  2010cited by this paper
• Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant

  2009cited by this paper
• A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

  2009cited by this paper
• Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

  2009cited by this paper
• Chemotherapy-induced nausea and vomiting.

  2008cited by this paper
• Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings

  2007cited by this paper
• Aprepitant as Salvage Therapy in Patients with Chemotherapy-Induced Nausea and Emesis Refractory to Prophylaxis with 5-HT3 Antagonists and Dexamethasone

  2006cited by this paper
• Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

  2005cited by this paper
• Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

  2005cited by this paper
• Chemotherapy-induced nausea and vomiting in routine practice: a European perspective

  2004cited by this paper
• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

  2004cited by this paper
• Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

  2003cited by this paper
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

  2003cited by this paper
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

  2003cited by this paper
• Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics

  2003cited by this paper
• Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

  2001cited by this paper
• Prevention of cisplatin-induced delayed emesis: still unsatisfactory

  2000cited by this paper
• Potential of Substance P Antagonists as Antiemetics

  2000cited by this paper
• Perception of chemotherapy side effects cancer versus noncancer patients.

  1999cited by this paper
• Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

  1999cited by this paper
• Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.

  1999cited by this paper
• Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

  1999cited by this paper
• Optimal control of acute cisplatin-induced emesis.

  1996cited by this paper
• Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

  1991cited by this paper
• Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

  1991cited by this paper
• Emesis as a critical problem in chemotherapy.

  1981cited by this paper

• Effects of Xiao-Ban-Xia-Tang on cisplatin and 1-PBG induced pica and gut microbiota in rats

  2022cites this paper
• Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

  2020cites this paper
• Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.

  2020cites this paper
• Effects of Xiao-Ban-Xia-Tang Formula on Cisplatin and 1-phenylbiguanide Hydrochloride Induced Emesis and Gut Microbiota in the Pica Model of Rats

  2020cites this paper
• Comparison of acute and delayed antiemetic effect of adding Aprepitant to Odansitron ‎and Dexamethasone regimen ‎in patients with Hodgkin lymphoma receiving highly emetogenic chemotherapy

  2019cites this paper
• Addition of aprepitant prevents chemotherapy-induced vomiting and nausea moderately when 5-Hydroxytryptamine-3 receptor antagonists and dexamethasone failed

  2017cites this paper
• Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic

  2017cites this paper
• An Unusual Cause of Subacute Headache in a Patient Undergoing Chemotherapy for Advanced Testicular Nonseminomatous Germ Cell Tumour

  2016cites this paper
• Comparison of three preclinical models for nausea and vomiting assessment.

  2016cites this paper